Bath & Body Works Stock Rises on Citi Upgrade; Klarna Falls on Guidance

In notable market movements, Bath & Body Works shares rose in pre-market trading after Citi upgraded the stock. Analyst Paul Lejuez cited a favorable risk/reward balance, raising the rating from 'neutral' to 'buy'. This development drew investor attention ahead of the company's earnings report expected next week. Meanwhile, shares of payment company Klarna fell sharply in pre-market trading after its annual revenue and gross merchandise volume guidance came in below expectations. The company cited currency pressures and a decline in volumes in Germany, though it managed to beat profit expectations for the second consecutive quarter. Amylyx Pharmaceuticals shares continued to climb, gaining up to 54% in early trading. The drug developer announced that its experimental drug met the primary goal in a late-stage clinical trial for treating patients with low blood sugar following obesity surgery. These developments highlight investor reactions to corporate news and analyst assessments. Bath & Body Works' earnings report remains a focus for the market. This is not investment advice.